Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Mercaptopurine (compound)


PubChem
Name: 6-Mercaptopurine
PubChem Compound ID: 2724350
Description: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Molecular formula: C5H6N4OS
Molecular weight: 170.193 g/mol
Synonyms:
Mercaptopurine hydrate; 6H-Purine-6-thione, 1,7-dihydro-, monohydrate; Mercaptopurine hydrate (JP15); CCRIS 5819; Purine-6-thiol, monohydrate; Purine-6-thiol monohydrate; 1,7-Dihydro-6H-purin-6-thion, monohydrat [Czech]; 6-Mercaptopurine monohydrate; 6-Merkaptopurin, monohydrat [Czech]; Mercaptopurine [BAN:INN:JAN].
show more »
DrugBank
Identification
Name: 6-Mercaptopurine
Name (isomeric): DB01033
Drug Type: small molecule
Description: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Synonyms:
6-Mercaptopurine; MP; 6 MP; Mercapurin; Mercaptopurine Monohydrate
Brand: Puri-Nethol, Leukerin, Ismipur, Mern, Mercaleukim, Mercaleukin, Purimethol, Purinethol, Leupurin
Category: Antimetabolites, Antimetabolites, Antineoplastic, Antineoplastic Agents, Purine analogues, Immunosuppressive Agents, Nucleic Acid Synthesis Inhibitors
CAS number: 50-44-2
Pharmacology
Indication: For remission induction and maintenance therapy of acute lymphatic leukemia.
Pharmacology:
Mercaptopurine is one of a large series of purine analogues which interfere with nucleic acid biosynthesis and has been found active against human leukemias. It is an analogue of the purine bases adenine and hypoxanthine. It is not known exactly which of any one or more of the biochemical effects of mercaptopurine and its metabolites are directly o...
show more »
Mechanism of Action:
Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). This intracellular nucleotide inhibits several reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP ...
show more »
Absorption: Clinical studies have shown that the absorption of an oral dose of mercaptopurine in humans is incomplete and variable, averaging approximately 50% of the administered dose. The factors influencing absorption are unknown.
Protein binding: Plasma protein binding averages 19% over the concentration range 10 to 50 µg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg).
Biotransformation: Hepatic. Degradation primarily by xanthine oxidase. The catabolism of mercaptopurine and its metabolites is complex. In humans, after oral administration of 35S-6-mercaptopurine, urine contains intact mercaptopurine, thiouric acid (formed by direct oxidation by xanthine oxidase, probably via 6-mercapto-8-hydroxypurine), and a number of 6-methylated thiopurines. The methylthiopurines yield appreciable amounts of inorganic sulfate.
Half Life: Triphasic: 45 minutes, 2.5 hours, and 10 hours.
Toxicity: Signs and symptoms of overdosage may be immediate such as anorexia, nausea, vomiting, and diarrhea; or delayed such as myelosuppression, liver dysfunction, and gastroenteritis. The oral LD50 of mercaptopurine was determined to be 480 mg/kg in the mouse and 425 mg/kg in the rat.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Preferably on an empty stomach, drink plenty of liquids, avoid alcohol.
Drug interaction:
AcenocoumarolMercaptopurine may decrease the anticoagulant effect of acenocoumarol.
DicumarolMercaptopurine may decrease the anticoagulant effect of dicumarol.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
VecuroniumThe agent dereases the effect of the muscle relaxant
AnisindioneMercaptopurine may decrease the anticoagulant effect of anisindione.
show more »

Targets


Enzymes


Transporters